BridgeMD
New treatment option for Obesity (Disorder)
Official title Impact of a Pro-diversity Gut Microbiota Diet After a Bariatric Surgery on Gut Microbiota, Eating Behaviour and Sensory Function
ClinicalTrials.gov ID: NCT07268508
What this study is testing
- What it's testing
- Bariatric surgery is the most effective treatment for long-term weight loss and reducing obesity-related health risks. It alters the gastrointestinal tract as well as metabolic and hormonal functions, influencing eating behaviour.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 25 to 65
You may be able to join if
- Between 25 and 65 years old
- Undergoing either sleeve gastrectomy or Roux-en-Y gastric bypass
- With grade 3 obesity (BMI≥40 kg/m²) or with BMI≥35 kg/m² and at least one comorbidity likely to be improved after surgery, with the exception of type...
- Signed consent form
- Living less than an hour and 30 minutes from the hospital
You likely can't join if
- Type 2 diabetes
- Presence of a contraindication to bariatric surgery
- Presence of gastrointestinal pathologies with an inflammatory component, known gastroparesis, total gastrectomy, colectomy, exocrine pancreatic...
- Claustrophobic
- Pregnant or breastfeeding women
- Taking an obesity treatment 3 months before surgery
See the full eligibility criteria
- Between 25 and 65 years old
- Undergoing either sleeve gastrectomy or Roux-en-Y gastric bypass
- With grade 3 obesity (BMI≥40 kg/m²) or with BMI≥35 kg/m² and at least one comorbidity likely to be improved after surgery, with the exception of type 2 diabetes
- Signed consent form
- Living less than an hour and 30 minutes from the hospital
- Presence of effective and stable contraception for women of childbearing potential
- Type 2 diabetes
- Presence of a contraindication to bariatric surgery
- Presence of gastrointestinal pathologies with an inflammatory component, known gastroparesis, total gastrectomy, colectomy, exocrine pancreatic insufficiency, known endocrine pathologies inducing hyperglycaemia...
- Claustrophobic
- Pregnant or breastfeeding women
- Taking an obesity treatment 3 months before surgery
- Taking a corticoids, immunosuppression, anabolizing, or growing hormones, antibody treatments less than 3 months before inclusion
- Daily taking of laxatives or drugs that can strongly interfere with the composition of the intestinal microbiota. If taken sporadically, the patient can be included at a distance (3 weeks) from the laxatives taken.
- Specific diets (vegetarian, vegan or without gluten)
- No French speaker
- Already included in other study
- Donated blood in the last two months
- Without freezer access
- With allergy or intolerance to food propose in ad libitum buffet
The study team makes the final eligibility decision.
Where it's taking place
- Lyon, France
- Pierre-Bénite, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 25 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Lyon, France; Pierre-Bénite, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.